Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Fig. 3

Anti-PD-L1 antibody in combination with sMIC-targeting mAb B10G5 cooperatively enhances antigen-specific CD8 T cell anti-tumor responses. a, Depiction of experiment schema. CFSE-labeled tumor antigen SV40TAg-specific TCR-I CD8 T cells were transferred into TRAMP/MICB mice that have received 4-week duration of therapy, which was continued post transfer of TCR-I CD8 T cells. Data shown are 14-day post-transfer of CFSE-labeled TCR-I CD8 T cells. b and c, Representative dot plots (b) and summary data (c) demonstrating the percentage of Db/I-tetramer+ SV40TAg-specific CD8 T cells in dLN, tumor infiltrates, and spleen. d and e, Representative histograms (d) and summary data (e) demonstrating proliferation of SV40Tag-specific CD8 T cells represented by CFSElo population. f and g, Representative histograms (f) and summary data (g) demonstrating the response of Db/I-tetramer+ SV40TAg-specific CD8 T cells to ex vivo SV40TAg peptide re-stimulation as measured by IFN╬│ production

Back to article page